Home › NCT05886218

Quantitative Neuromuscular Monitoring and Gastric Bypass Surgery

A Before/After Study of the Impact of Quantitative Neuromuscular Monitoring and Sugammadex Reversal Following Gastric Bypass Surgery

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* age greater than 18 years
* scheduled for an elective laparoscopic gastric bypass procedure

Exclusion Criteria:

* age less than 18 years
* pregnancy
* prisoners
* significant co-existing lung disease including asthma or chronic obstructive pulmonary disease (COPD) requiring regular medication
* patients who require supplemental oxygen pre-operatively to maintain a hemoglobin saturation (SpO2\>98%)

About the study

This is a single site, prospective, non-blinded, non-randomized, before/after study. This study is designed to evaluate the impact of monitoring and reversal guidelines for neuromuscular blocking drugs on the post-operative outcomes for patients undergoing laparoscopic gastric bypass surgery.

What is being tested

• Quantitative Neuromuscular Function Monitoring (device)

Sponsor: University of California, Davis · Participants: 215 · Started: Feb 8, 2023

Contact the study team

• Ana P Arias, BS · Phone: 916-703-5456
• Julio J Arana Pineda, BA · Phone: 916-734-4074

Official record on ClinicalTrials.gov — NCT05886218

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.